S&P 500   3,617.46 (-0.57%)
DOW   29,566.29 (-1.15%)
QQQ   299.16 (+0.05%)
AAPL   120.54 (+3.39%)
MSFT   212.68 (-1.18%)
FB   275.87 (-0.70%)
GOOGL   1,755.11 (-1.79%)
AMZN   3,164.59 (-0.96%)
TSLA   579.92 (-1.00%)
NVDA   532.16 (+0.32%)
BABA   264.29 (-4.41%)
CGC   28.78 (-0.76%)
GE   10.27 (-1.25%)
MU   64.24 (+0.02%)
AMD   92.37 (+5.94%)
T   28.77 (-0.90%)
NIO   51.47 (-4.69%)
F   9.12 (+0.33%)
ACB   11.71 (+11.84%)
NFLX   488.34 (-0.61%)
BA   211.68 (-2.23%)
GILD   59.90 (-0.22%)
DIS   147.44 (+0.21%)
S&P 500   3,617.46 (-0.57%)
DOW   29,566.29 (-1.15%)
QQQ   299.16 (+0.05%)
AAPL   120.54 (+3.39%)
MSFT   212.68 (-1.18%)
FB   275.87 (-0.70%)
GOOGL   1,755.11 (-1.79%)
AMZN   3,164.59 (-0.96%)
TSLA   579.92 (-1.00%)
NVDA   532.16 (+0.32%)
BABA   264.29 (-4.41%)
CGC   28.78 (-0.76%)
GE   10.27 (-1.25%)
MU   64.24 (+0.02%)
AMD   92.37 (+5.94%)
T   28.77 (-0.90%)
NIO   51.47 (-4.69%)
F   9.12 (+0.33%)
ACB   11.71 (+11.84%)
NFLX   488.34 (-0.61%)
BA   211.68 (-2.23%)
GILD   59.90 (-0.22%)
DIS   147.44 (+0.21%)
S&P 500   3,617.46 (-0.57%)
DOW   29,566.29 (-1.15%)
QQQ   299.16 (+0.05%)
AAPL   120.54 (+3.39%)
MSFT   212.68 (-1.18%)
FB   275.87 (-0.70%)
GOOGL   1,755.11 (-1.79%)
AMZN   3,164.59 (-0.96%)
TSLA   579.92 (-1.00%)
NVDA   532.16 (+0.32%)
BABA   264.29 (-4.41%)
CGC   28.78 (-0.76%)
GE   10.27 (-1.25%)
MU   64.24 (+0.02%)
AMD   92.37 (+5.94%)
T   28.77 (-0.90%)
NIO   51.47 (-4.69%)
F   9.12 (+0.33%)
ACB   11.71 (+11.84%)
NFLX   488.34 (-0.61%)
BA   211.68 (-2.23%)
GILD   59.90 (-0.22%)
DIS   147.44 (+0.21%)
S&P 500   3,617.46 (-0.57%)
DOW   29,566.29 (-1.15%)
QQQ   299.16 (+0.05%)
AAPL   120.54 (+3.39%)
MSFT   212.68 (-1.18%)
FB   275.87 (-0.70%)
GOOGL   1,755.11 (-1.79%)
AMZN   3,164.59 (-0.96%)
TSLA   579.92 (-1.00%)
NVDA   532.16 (+0.32%)
BABA   264.29 (-4.41%)
CGC   28.78 (-0.76%)
GE   10.27 (-1.25%)
MU   64.24 (+0.02%)
AMD   92.37 (+5.94%)
T   28.77 (-0.90%)
NIO   51.47 (-4.69%)
F   9.12 (+0.33%)
ACB   11.71 (+11.84%)
NFLX   488.34 (-0.61%)
BA   211.68 (-2.23%)
GILD   59.90 (-0.22%)
DIS   147.44 (+0.21%)
Log in
OTCMKTS:NVZMY

Novozymes A/S Stock Forecast, Price & News

$57.66
+0.80 (+1.41 %)
(As of 11/27/2020 08:28 PM ET)
Add
Compare
Today's Range
$57.41
Now: $57.66
$57.83
50-Day Range
$56.26
MA: $61.36
$65.67
52-Week Range
$37.99
Now: $57.66
$66.75
Volume8,100 shs
Average Volume35,780 shs
Market Capitalization$17.13 billion
P/E Ratio36.73
Dividend Yield0.90%
Beta0.57
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop production, and animal health and nutrition solutions; liquefaction, saccharifaction, fermentation, lignecellulosic hydrolysis, and process enhancement solutions for bioenergy; baking, beverages, dairy, starch, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry. It also provides wastewater solutions, such as additives, biogas production, industrial bio cleaning, compound removal, odor control, and system start-up solutions; and textile solutions comprising denim finishing and abrasion, biopreparation, biopolishing bleach clean-up, and desizing solutions. In addition, the company offers forest products that include bleach boosting, deinking, fiber modification, effluent control, pitch and stickies control, and starch modification products; and leather solutions, which comprise biopreparation, degreasing, and re-bating. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis; and rTrypsin for cell culture. Novozymes A/S has a strategic collaboration with Boehringer Ingelheim Animal Health for the research, development, production, marketing, and sale of a portfolio of probiotic products; and development agreement with CARBIOS to produce enzyme for recycling of pet-plastics and fibers. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Read More
Novozymes A/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.8Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.94 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
Current SymbolOTCMKTS:NVZMY
CUSIPN/A
CIKN/A
Phone45-4446-0000
Employees6,125

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.16 billion
Cash Flow$1.48 per share
Book Value$5.79 per share

Profitability

Net Income$472.79 million

Miscellaneous

Market Cap$17.13 billion
Next Earnings Date12/2/2020 (Estimated)
OptionableNot Optionable
$57.66
+0.80 (+1.41 %)
(As of 11/27/2020 08:28 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVZMY News and Ratings via Email

Sign-up to receive the latest news and ratings for NVZMY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novozymes A/S (OTCMKTS:NVZMY) Frequently Asked Questions

How has Novozymes A/S's stock been impacted by Coronavirus?

Novozymes A/S's stock was trading at $45.0314 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVZMY shares have increased by 28.0% and is now trading at $57.66.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Novozymes A/S?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novozymes A/S in the last year. There are currently 5 sell ratings and 2 hold ratings for the stock, resulting in a consensus recommendation of "Sell."
View analyst ratings for Novozymes A/S
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Novozymes A/S?

Wall Street analysts have given Novozymes A/S a "Sell" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novozymes A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Novozymes A/S's next earnings date?

Novozymes A/S is scheduled to release its next quarterly earnings announcement on Wednesday, December 2nd 2020.
View our earnings forecast for Novozymes A/S
.

How were Novozymes A/S's earnings last quarter?

Novozymes A/S (OTCMKTS:NVZMY) posted its earnings results on Wednesday, April, 29th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.42. The biotechnology company had revenue of $558.75 million for the quarter. Novozymes A/S had a return on equity of 27.20% and a net margin of 20.73%.
View Novozymes A/S's earnings history
.

How often does Novozymes A/S pay dividends? What is the dividend yield for Novozymes A/S?

Novozymes A/S declared an annual dividend on Friday, January 24th. Stockholders of record on Friday, February 28th will be given a dividend of $0.517 per share on Tuesday, March 17th. This represents a yield of 1.01%. The ex-dividend date is Thursday, February 27th. This is an increase from Novozymes A/S's previous annual dividend of $0.50.
View Novozymes A/S's dividend history
.

Are investors shorting Novozymes A/S?

Novozymes A/S saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 7,200 shares, an increase of 20.0% from the October 15th total of 6,000 shares. Based on an average daily volume of 18,000 shares, the days-to-cover ratio is currently 0.4 days.
View Novozymes A/S's Short Interest
.

Who are some of Novozymes A/S's key competitors?

Who are Novozymes A/S's key executives?

Novozymes A/S's management team includes the following people:
  • Mr. Lars Green MSc, Exec. VP & CFO (Age 53)
  • Dr. Thomas Videbaek, EVP of Strategy & Bus. Transfotmation, People and Sustainability & Brand (Age 60)
  • Mr. Anders Lund, Exec. VP of Consumer Biosolutions (Age 47)
  • Ms. Tina SejersgÃ¥rd Fanø, Exec. VP of Agriculture & Industrial Biosolutions (Age 51)
  • Ms. Ester Baiget, Pres & CEO
  • Ms. Graziela Chaluppe dos Santos Malucelli, Exec. VP of Operations, Supply & Quality
  • Mr. Tobias Cornelius Bjorklund, Head of Investor Relations
  • Mr. Tue Micheelsen, VP of Global Sales & Marketing
  • Mr. Pedro Luiz Fernandes, Head of Corp. Affairs & Sustainability - Novozymes Latin America
  • Mr. Sebastian Søderberg, VP and Head of New Bus. Devel. - Incubations & Acquisitions

What is Novozymes A/S's stock symbol?

Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMY."

How do I buy shares of Novozymes A/S?

Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novozymes A/S's stock price today?

One share of NVZMY stock can currently be purchased for approximately $57.66.

How big of a company is Novozymes A/S?

Novozymes A/S has a market capitalization of $17.13 billion and generates $2.16 billion in revenue each year. The biotechnology company earns $472.79 million in net income (profit) each year or $1.65 on an earnings per share basis. Novozymes A/S employs 6,125 workers across the globe.

What is Novozymes A/S's official website?

The official website for Novozymes A/S is www.novozymes.com.

How can I contact Novozymes A/S?

Novozymes A/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.